In response to the situation in the system of registration/declaration of changes in wholesale and retail prices for medicinal products and medical products (hereinafter – the system of registration/price declaration), which as a result leads to the suspension of public procurement, the Association expresses its position with this appeal and a vision of the necessary measures to resolve the situation.

First of all, we would like to note that the current price registration/declaration procedure, approved by CMU Resolution No. 240 of July 2, 2014 “On reference pricing for medicinal products and medical products purchased from the state and local budgets” is overloaded and detached from the logic of the process of providing patients with medicines. Not being integrated into the general system of reimbursing the cost of outpatient drug consumption – reimbursement, and not having a balance in the form of a compensatory mechanism, it turned into a mechanism of direct restrictive regulation of drug prices, which carries a number of dangers for both the patient and the state. We will remind that in June of last year, during the discussion of drafts of the relevant resolution and procedures, the Association addressed the heads of the Government and ministries regarding the risks of introducing such a mechanism in isolation from the reimbursement system. As of today, we are sorry to see that the warnings of the professional industry have been fully implemented. Instead of the declared goal – to increase the availability of medicines for the population, the procedure, bureaucratized and overloaded with calculations and volumes of requested information, became a significant barrier to patients’ access to the necessary medicines.